Upadacitinib Bests Dupilumab in Atopic Dermatitis Trial
The randomized, double-blind, double-dummy, active-controlled Heads Up study included 692 patients aged 18 to 75 years with moderate to severe atopic dermatitis who are candidates for systemic therapy.